natgillin/translations-raw huggingface dataset:
Based on retention in treatment and the percentage of thrice-weekly urine samples negative for non-study opioids, buprenorphine was more effective than the low dose of the control, in keeping heroin addicts in treatment and in reducing their use of opioids while in treatment. 
Na temelju broja ispitanika koji su ostali na liječenju i postotka uzoraka urina prikupljanih tri puta tjedno i negativnih na opioide izvan ispitivanja, buprenorfin se pokazao učinkovitijim u zadržavanju heroinskih ovisnika na liječenju i u smanjivanju njihove uporabe opioida za vrijeme liječenja, nego nisko dozirana aktivna kontrola.
• anxiety, depression, decreased sexual drive, nervousness, abnormal thinking 
• tjeskoba, depresija, smanjen seksualni nagon, nervoza, poremećaj razmišljanja
In a double-blind, double-dummy, parallel-group study comparing buprenorphine ethanolic solution to a full agonist active control, 162 subjects were randomised to receive the ethanolic sublingual solution of buprenorphine at 8 mg/day (a dose which is roughly comparable to a dose of 12 mg/day of buprenorphine/naloxone), or two relatively low doses of active control, one of which was low enough to serve as an alternative to placebo, during a 3 to10 day induction phase, a 16-week maintenance phase and a 7-week detoxification phase. 
U dvostruko slijepom ispitivanju s dvije kontrole na paralelnim skupinama, u kojem se uspoređivala etanolna otopina buprenorfina s aktivnom kontrolom punog agonista, 162 ispitanika su randomizirana primati sublingvalno 8 mg/dan etanolne otopine buprenorfina (doza koja je ugrubo usporediva s dozom od 12 mg/dan buprenorfina/naloksona), ili dvije relativno niske doze aktivne kontrole, od kojih je jedna bila dovoljno niska da služi kao alternativa placebu, tijekom 3 do 10 dana faze uvođenja, 16 tjedana faze održavanja i 7 tjedana faze detoksikacije.
• sudden withdrawal syndrome caused by taking product too soon after use of illicit opioids, drug withdrawal syndrome in newborn 
• iznenadni sindrom ustezanja uzrokovan preranim uzimanjem lijeka nakon primjene zabranjenih opioida, sindrom ustezanja lijeka u novorođenčadi.
Moderate Hepatic Impairment (Child-Pugh Class B) (n=8) 
Umjereno oštećenje jetre (Child-Pughov stupanj B) (n=8)
Naloxone is metabolised in the liver, primarily by glucuronide conjugation, and excreted in the urine. 
Nalokson se metabolizira u jetri, primarno konjugacijom s glukuronskom kiselinom, a izlučuje se urinom.
Buprenorphine/naloxone may cause drowsiness, particularly when taken together with alcohol or central nervous system depressants (such as tranquilisers, sedatives or hypnotics) (see section 4.5). 
Buprenorfin/nalokson može uzrokovati omamljenost, osobito ako se uzme zajedno s alkoholom ili depresorima središnjeg živčanog sustava (kao što su sredstva za umirenje, sedativi ili hipnotici) (vidjeti dio 4.5).
Zubsolv is not interchangeable with other buprenorphine products. 
Zubsolv se ne može međusobno mijenjati s drugim lijekovima buprenorfina.
These underlying factors must be taken into consideration before prescribing buprenorphine/naloxone and during treatment. 
Spomenuti čimbenici moraju se uzeti u obzir prije propisivanja buprenorfina/naloksona kao i tijekom samog liječenja.
Regular monitoring of liver function is recommended (see section 4.4) 
Preporuča se redovito praćenje jetrene funkcije (vidjeti dio 4.4)
Leukocytosis Leukopenia Lymphadenopathy Thrombocytopenia 
Leukocitoza Leukopenija Limfadenopatija Trombocitopenija
Decreased appetite Hyperglycaemia Hyperlipidaemia Hypoglycaemia 
Smanjeni apetit Hiperglikemija Hiperlipidemija Hipoglikemija
After a satisfactory stabilisation has been achieved the frequency of dosing may be decreased to dosing every other day at twice the individually titrated daily dose. 
Nakon što se postigla zadovoljavajuća stabilizacija, učestalost doziranja može se smanjiti na doziranje svaki drugi dan, s time da se daje dvostruka dnevna doza koju pojedini bolesnik inače prima.
Liver damage has been reported after taking buprenorphine/naloxone, especially when the medicine is misused. 
Zabilježeni su slučajevi oštećenja jetre nakon uzimanja lijeka buprenorfina/naloksona, osobito prilikom pogrešne uporabe lijeka.
• Liver damage 
• Oštećenje jetre
As buprenorphine/naloxone pharmacokinetics may be altered in patients with hepatic impairment, lower initial doses and careful dose titration in patients with mild to moderate hepatic impairment are recommended (see section 5.2). 
S obzirom na to da farmakokinetika buprenorfina/naloksona može biti izmijenjena u bolesnika s oštećenjem jetre, preporučuju se niže početne doze i pažljivo titriranje doze u bolesnika s blagim do umjerenim oštećenjem jetre (vidjeti dio 5.2).
• migraines, dizziness, fainting, increase in muscle tension, tingling, drowsiness 
• migrene, omaglica, nesvjestica, povećana napetost mišića, trnci, omamljenost
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP. 
• Plan upravljanja rizikom (RMP) Nositelj odobrenja obavljat će zadane farmakovigilancijske aktivnosti i intervencije, detaljno objašnjene u dogovorenom Planu upravljanja rizikom (RMP), koji se nalazi u Modulu 1.8.2
• have low blood pressure, enlarged prostate gland or difficulties passing water because of narrowing of the urethra 
• ako imate nizak krvni tlak, uvećanu prostatu ili poteškoće s mokrenjem zbog sužene uretre
Hallucination 
Halucinacije
No dose modification based on renal function is required but caution is recommended when dosing subjects with severe renal impairment (see section 4.4). 
Nije potrebna prilagodba doze vezano uz funkciju bubrega, ali se preporučuje oprez kad se doza primjenjuje u bolesnika s teškim oštećenjem funkcije bubrega (vidjeti dio 4.4).
Cases of acute hepatic injury have been reported in opioid-dependent addicts both in clinical trials and in post marketing adverse reaction reports. 
Slučajevi akutnog oštećenja jetre prijavljeni su u ovisnika o opioidima u kliničkim ispitivanjima kao i u prijavama nuspojava nakon stavljanja lijeka u promet.
Hepatitis Hepatitis acute Jaundice Hepatic necrosis Hepatorenal syndrome 
Žutica Hepatička nekroza Hepatorenalni sindrom
Intravenous or intranasal misuse of Zubsolv is expected to be less likely than buprenorphine alone since the naloxone in Zubsolv can precipitate withdrawal in individuals dependent on heroin, methadone, or other opioid agonists. 
Manje je vjerojatna intravenska ili intranazalna pogrešna uporaba lijeka Zubsolv nego samog buprenorfina, s obzirom da nalokson u lijeku Zubsolv može izazvati simptome ustezanja u pojedinaca ovisnih o heroinu, metadonu ili drugim agonistima opioida.
Pack-size of 28 (4 x 7) tablets. 
Veličina pakiranja od 28 (4 x 7) tableta.
Pack-size of 7 (1 x 7) tablets. 
Veličina pakiranja od 7 (1 x 7) tableta.
“8.6” on one side 
„8.6” na jednoj strani
Table 3 summarizes the results from a clinical trial in which the exposure after single-dose administration of buprenorphine/naloxone sublingual tablet was determined in healthy subjects, and in subjects with hepatic impairment. 
Tablica 3 sažeto prikazuje rezultate kliničkog ispitivanja u kojem je izloženost nakon primjene jednokratne doze sublingvalne tablete buprenorfina/naloksona utvrđena u zdravih ispitanika i ispitanika s oštećenjem jetre.
Signs of overdose may also include somnolence, amblyopia, miosis, hypotension, nausea, vomiting and/or speech disorders. 
Znakovi predoziranja također mogu uključivati somnolenciju, ambliopiju, miozu, hipotenziju, mučninu,
The other ingredients are mannitol, citric acid anhydrous, sodium citrate, microcrystalline cellulose, croscarmellose sodium, sucralose, levomenthol, colloidal anhydrous silica and sodium stearyl fumarate. 
Drugi sastojci su manitol, citratna kiselina, bezvodna, natrijev citrat, mikrokristalična celuloza, umrežena karmelozanatrij, sukraloza, levomentol, silicijev dioksid, koloidni, bezvodni i natrijev stearilfumarat.
The spectrum of abnormalities ranges from transient asymptomatic elevations in hepatic transaminases to hepatic failure, hepatic necrosis, hepatorenal syndrome, hepatic encephalopathy and death. 
Poremećaji su se kretali u rasponu od prolaznih asimptomatskih povišenja jetrenih transaminaza do zatajenja jetre, nekroze jetre, hepatorenalnog sindroma, hepatalne encefalopatije i smrti.
If you are dependent upon heroin or a short acting opioid, your first dose of Zubsolv should be taken when signs of withdrawal appear, but not less than 6 hours after you last used opioids 
Ako ste ovisni o heroinu ili kratkodjelujućim opioidima, prvu dozu lijeka Zubsolv trebate uzeti kad se pojave znakovi ustezanja, no ne ranije od 6 sati od zadnjeg uzimanja opioida.
• weakness, chest pain, chills, fever, feeling of general discomfort, pain, swelling (hands and feet) 
• slabost, bol u prsnom košu, zimica, vrućica, osjećaj opće nelagode, bol, oticanje (ruku i stopala)
Patients who are positive for viral hepatitis, receiving concomitant medicinal products (see section 4.5) and/or have existing liver dysfunction are at risk of accelerated liver injury. 
Bolesnici koji su pozitivni na virusni hepatitis, koji istodobno uzimaju druge lijekove (vidjeti dio 4.5) i/ili imaju postojeći poremećaj jetrene funkcije izloženi su opasnosti od ubrzanog oštećenja jetre.
Opioids should be used with caution in patients with myxoedema, hypothyroidism, or adrenal cortical insufficiency (e.g., Addison's disease). 
Opioide je potrebno koristiti uz oprez u bolesnika s miksedemom, hipotireoidizmom ili insuficijencijom adrenalnog korteksa (npr. Addisonova bolest).
Opioids should be used with caution in patients with hypotension, prostatic hypertrophy or urethral stenosis. 
Opioide je potrebno koristiti uz oprez u bolesnika s hipotenzijom, hipertrofijom prostate ili stenozom uretre.
• increased blood pressure, flushing 
• povišen krvni tlak, navale crvenila
• abnormal liver function, weight loss 
• poremećaj jetrene funkcije, gubitak tjelesne težine
Do not swallow or consume food or any drink until the tablet is completely dissolved. 
Nemojte gutati ili konzumirati hranu ili bilo kakvo piće dok se tableta potpuno ne rastopi.
• are debilitated 
• ako ste u oslabljenom stanju
Reproduction studies by oral administration of buprenorphine: naloxone (ratio 1:1) indicated that embryolethality occurred in rats in the presence of maternal toxicity at all doses. 
Ispitivanja utjecaja na reprodukciju u štakora pokazala su da peroralno primijenjeni buprenorfin i nalokson (u omjeru 1:1) imaju letalne učinke na embrije štakora pri svim maternalno toksičnim dozama.
If a patient is changed between buprenorphine or buprenorphine and naloxone containing products, dose adjustments may be necessary due to the potential differences in bioavailability (see sections 4.4 and 5.2). 
Ako je bolesnik prelazio s lijekova koji sadrže buprenorfin ili buprenorfin i nalokson, možda će biti potrebne prilagodbe doze zbog potencijalnih razlika u bioraspoloživosti (vidjeti dijelove 4.4 i 5.2).
• Do not consume any food or drink until the tablets have completely dissolved. 
• Nemojte konzumirati hranu ili piće dok se tablete potpuno ne otope.
Concomitant administration of opioid antagonists (naltrexone, nalmefene) for the treatment of alcohol or opioid dependence. 
Istovremena primjena antagonista opioida (naltrekson, nalmefen) za liječenje ovisnosti o alkoholu ili opioidima.
“2.9” on one side 
„2.9” na jednoj strani
Abrupt discontinuation of treatment is not recommended as it may result in withdrawal syndrome with delayed onset. 
Ne preporučuje se nagli prekid terapije, jer on može uzrokovati sindrom ustezanja od lijeka koji može imati odgođeni nastup.
• Breathing problems (see also ‘Do not take Zubsolv' above ) Some people have died from respiratory failure (inability to breathe) because they misused this medicine or took it in combination with other central nervous system depressants, such as alcohol, benzodiazepines (tranquilisers), or other opioids. 
Neke su osobe umrle zbog zatajenja disanja (nisu mogle disati), jer su uzele ovaj lijek na pogrešan način ili su ga uzele u kombinaciji s drugim depresorima središnjeg živčanog sustava, kao što su alkohol, benzodiazepini (sredstva za umirenje) ili drugi opioidi.
Transaminases increased 
Povišene vrijednosti transaminaza
The lowest dose studied represented exposure multiples of 1x for buprenorphine and 5 x for naloxone at the maximum human therapeutic dose calculated on a mg/m² basis. 
Najniža ispitivana doza kojoj su štakori bili izloženi odgovarala je umnošcima od 1x izloženosti za buprenorfin i 5x za nalokson pri maksimalnoj terapijskoj dozi za ljude izračunate na temelju mg/m².
Overall, buprenorphine plasma exposure increased approximately 3-fold in patients with severely impaired hepatic function, while naloxone plasma exposure increased 14-fold with severely impaired hepatic function. 
Sveukupno, izloženost buprenorfina u plazmi povećana je približno 3 puta, a izloženost naloksona u plazmi povećana je 14 puta u bolesnika s teškim oštećenjem jetre.
• abnormal blood tests swollen, glands (lymph nodes) 
• neuobičajeni rezultati krvnih pretraga, otečene žlijezde (limfni čvorovi)
Amnesia Hyperkinesia Seizure 
Amnezija Hiperkinezija Napadaji
“11.4” on one side 
„11.4” na jednoj strani
Combining buprenorphine with naloxone in Zubsolv is intended to deter misuse and abuse of the buprenorphine. 
Kombiniranje buprenorfina s naloksonom u lijeku Zubsolv namijenjeno je odvraćanju od pogrešne uporabe i zlouporabe buprenorfina.
Very common side effects (may affect more than one in 10 people): 
Vrlo česte nuspojave (mogu se javiti u više od 1 na 10 osoba):
Zubsolv sublingual tablets should be used with caution in patients with moderate hepatic impairment (see sections 4.2 and 5.2). 
Zubsolv sublingvalne tablete trebaju se primjenjivati s oprezom u bolesnika s umjerenim oštećenjem jetre (vidjeti dijelove 4.2 i 5.2).
Less than daily dosing 
Doziranje rjeđe od jednom dnevno
• pain and sores in mouth, tongue discolouration 
• bol i ranice u ustima, promjena boje jezika
Medicinal product subject to special and restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2). 
Lijek se izdaje na poseban i ograničeni recept (vidjeti Prilog I.: Sažetak opisa svojstava lijeka, dio
Patients should not swallow or consume food or drink until the tablet is completely dissolved. 
Bolesnici ne smiju gutati niti konzumirati hranu ili tekućinu dok se tableta u potpunosti ne otopi.
How Zubsolv works 
Kako Zubsolv djeluje
The tablet is to be placed under the tongue until completely dissolved. 
Tableta se treba držati pod jezikom dok se potpuno ne otopi.
A reduction of the buprenorphine/naloxone dose may be needed. 
Stoga može biti potrebno sniziti dozu buprenorfina/naloksona.
In patients with marked drug dependence, initial administration of buprenorphine can produce a drug withdrawal syndrome similar to that associated with naloxone (see sections 4.2 and 4.4). 
U bolesnika s izraženom ovisnosti o lijeku, početna primjena buprenorfina može uzrokovati sindrom ustezanja od lijeka sličan onom uzrokovanom primjenom naloksona (vidjeti dijelove 4.2 i 4.4).
• severe tiredness, itching with yellowing of skin or eyes. 
• jak umor, svrbež sa žutom bojom kože ili očiju.
There are no adequate data from the use of buprenorphine/naloxone in pregnant women. 
Nema podataka o primjeni buprenorfina/naloksona u trudnica.
Buprenorphine is a partial agonist at the μ (mu)-opiate receptor and chronic administration produces dependence of the opioid type. 
Buprenorfin je parcijalni agonist µ (mi)-opioidnih receptora i kronična primjena dovodi do ovisnosti opioidnog tipa.
A carcinogenicity study with buprenorphine/naloxone was conducted in rats at doses of 7, 30 and 120 mg/kg/day, with estimated dose multiples of 3 to75 times, based on a Zubsolv equivalent human daily sublingual dose of 11.4 mg of buprenorphine calculated on a mg/m² basis. 
Ispitivanje kancerogenosti buprenorfina/naloksona provedeno je na štakorima s dozama od 7, 30 i 120 mg/kg/dan, čime su štakori bili izloženi 3 do 75 puta višoj dozi, s obzirom na dnevnu sublingvalnu dozu ekvivalenta Zubsolva buprenorfina za ljude od 11,4 mg izračunatu na temelju mg/m².
It is unknown whether naloxone/metabolites are excreted in human milk. 
Nije poznato izlučuju li se nalokson/metaboliti u majčino mlijeko.
• protein in your urine, urinary tract infection, difficulty urinating, painful or difficult urination, 
• nalaz proteina u urinu, infekcija mokraćnih puteva, bolno ili otežano mokrenje, krv u mokraći,
Tell your doctor if you are pregnant or intend to become pregnant. 
Ako ste trudni ili planirate trudnoću obavijestite svog liječnika.
• Keep the tablets in place under the tongue until they have completely dissolved 
• Držite tablete na mjestu pod jezikom sve dok se potpuno ne otope.
• Blood pressure 
• Krvni tlak
If you forget to take Zubsolv 
Ako ste zaboravili uzeti Zubsolv
• rapid or slow heartbeat, myocardial infarction (heart attack), palpitations, chest tightness 
• ubrzani ili usporeni otkucaji srca, infarkt miokarda (srčani udar), osjećaj lupanja srca, stezanje u prsnom košu
“5.7” on one side 
„5.7” na jednoj strani
For subjects randomised to either active treatment, dosing began with 8 mg of buprenorphine on Day 1, followed by 16 mg (two 8 mg) of buprenorphine on Day 2. 
Za ispitanike randomizirane u jednu od dvije skupine koje su primale djelatnu tvar, doziranje je započelo s 8 mg buprenorfina 1. dana, a 2. dana ispitanici su dobili 16 mg (dvaput po 8 mg) buprenorfina.
Buprenorphine, when taken orally, undergoes first-pass metabolism with N-dealkylation and glucuroconjugation in the small intestine and the liver. 
Kad se uzima peroralno, buprenorfin se metabolizira pri prvom prolasku N-dealkilacijom i konjugacijom s glukuronskom kiselinom u tankom crijevu i jetri.
Warnings and precautions • Misuse, abuse and diversion 
Upozorenja i mjere opreza • Pogrešna uporaba, zlouporaba i uporaba lijeka u svrhe za koje nije namijenjen
In comparative bioavailability studies Zubsolv 11.4/2.9 mg displayed equivalent buprenorphine exposure to 16/4mg (2 x 8/2mg) buprenorphine/naloxone administered as conventional sublingual tablets however Zubsolv 2 x 1.4/0.36 mg displayed 20% lower buprenorphine exposure to 2 x 2/0.5 mg buprenorphine/naloxone administered as conventional sublingual tablets. 
U ispitivanjima usporedivosti bioraspoloživosti, Zubsolv 11,4/2,9 mg pokazao je ekvivalentnu izloženost buprenorfina u odnosu na 16/4 mg (2 x 8/2 mg) buprenorfina/naloksona primijenjenih kao konvencionalne sublingvalne tablete, no Zubsolv 2 x 1,4/0,36 mg pokazali su 20 % nižu izloženost buprenorfina u odnosu na 2 x 2/0,5 mg buprenorfina/naloksona primijenjenih kao konvencionalne sublingvalne tablete.
Both active substances of Zubsolv, buprenorphine and naloxone, are extensively metabolized in the liver, and the plasma levels were found to be higher for both buprenorphine and naloxone in patients with moderate and severe hepatic impairment. 
Obje djelatne tvari lijeka Zubsolv, buprenorfin i nalokson, opsežno se metaboliziraju u jetri i utvrđeno je da su njihove izmjerene razine u plazmi više u bolesnika s umjerenim i teškim oštećenjem jetre.
Abnormal dreams Agitation Apathy 
Agitacija Apatija
The reduced level of alertness can make driving and using machines hazardous 
Smanjenja razina pažnje može povećavati rizik pri upravljanju vozilima i strojevima.
Stopping treatment suddenly may cause withdrawal symptoms. 
Nagli prekid liječenja može prouzročiti simptome ustezanja lijeka.
Therefore, patients should be monitored when changing between different buprenorphine containing products as differences in bioavailability (see section 5.2) may be noticeable in some individual cases. 
Zato je potrebno pratiti bolesnike kada prelaze s jednog lijeka koji sadrži buprenorfin na drugi, budući da u pojedinim slučajevima može biti zamjetnih razlika u bioraspoloživosti (vidjeti dio 5.2).
Zubsolv tablet description Zubsolv tablet debossing 
Opis Zubsolv tablete Utisnuta oznaka Zubsolv tablete
Table 1: Treatment related adverse reactions reported in clinical trials and post-marketing surveillance of buprenorphine/naloxone 
Tablica 1: Nuspojave vezane uz liječenje, prijavljene u kliničkim ispitivanjima i nuspojave zabilježene nakon stavljanja buprenorfina/naloksona u promet Klasa sustava organa
An additional Zubsolv 1.4 mg / 0.36 mg or 2.9 mg / 0.71 mg may be administered on day one depending on the individual patient's requirement. 
Dodatna doza lijeka Zubsolv od 1,4 mg / 0,36 mg ili 2,9 mg / 0,71 mg može se primijeniti prvog dana ovisno o potrebama pojedinog bolesnika.
Buprenorphine/naloxone is contraindicated in patients with severe hepatic impairment (see sections 4.3 and 5.2). 
Buprenorfin/nalokson kontraindiciran je u bolesnika s teškim oštećenjem jetre (vidjeti dijelove 4.3 i 5.2).
Opioid agonist ceiling effects were observed during clinical pharmacology studies in opioid-dependent patients. 
U ispitivanjima kliničke farmakologije primijećeni su „učinci plafona” uz opioidne agoniste u bolesnika ovisnih o opioidima.
Starting treatment 
Početak liječenja
one tablet of Zubsolv 1.4 mg / 0.36 mg each day, or 
- jedna tableta lijeka Zubsolv 1,4 mg / 0,36 mg svaki dan ili
• Withdrawal symptoms 
• Simptomi ustezanja
A patent airway and assisted or controlled ventilation must be assured. 
Mora se osigurati prohodnost dišnih puteva te asistirano ili kontrolirano disanje.
“1.4” on one side 
„1.4” na jednoj strani
The concomitant use of monoamine oxidase inhibitors (MAOI) might produce an exaggeration of opioid effects, based on experience with morphine (see section 4.5). 
Na temelju iskustva s morfijem, istovremena primjena inhibitora monoaminooksidaze (MAOI) može pojačati učinke opioida (vidjeti dio 4.5).
To avoid precipitating withdrawal, induction with buprenorphine/naloxone should be undertaken when objective signs of withdrawal are evident (see section 4.2). 
Da bi se izbjeglo izazivanje simptoma ustezanja, uvođenje buprenorfina/naloksona treba se poduzeti nakon očitih objektivnih simptoma ustezanja (vidjeti dio 4.2).
Heat stroke 
Toplinski udar
Caution is recommended when dosing patients with severe renal impairment (creatinine clearance <30 ml/min) (see sections 4.4 and 5.2). 
Preporučuje se oprez pri doziranju u bolesnika s teškim oštećenjem bubrega (klirens kreatinina < 30 ml/min) (vidjeti dijelove 4.4 i 5.2).
The dose of buprenorphine or the CYP3A4 inducer may need to be adjusted accordingly 
U skladu s tim potrebno je prilagoditi dozu buprenorfina ili induktora CYP3A4.
Caution is recommended when dosing patients with severe renal impairment (creatinine clearance <30 ml/min) (see sections 4.2 and 5.2). 
Preporučuje se oprez pri doziranju u bolesnika s teškim oštećenjem bubrega (klirens kreatinina <30 ml/min) (vidjeti dijelove 4.2 i 5.2).
The effect of hepatic impairment on the pharmacokinetics of buprenorphine and naloxone were evaluated in a post-marketing study. 
Učinak oštećenja jetre na farmakokinetiku buprenorfina i naloksona procijenjen je u ispitivanju nakon stavljanja lijeka u promet.
Keep the tablet under your tongue until it dissolves. 
Tabletu držati pod jezikom dok se ne rastopi.
2.8-fold increase 
4.8 Nuspojave
Not all strengths and pack-sizes may be marketed. 
Na tržištu se ne moraju nalaziti sve jačine.
It also contains naloxone which is used to deter intravenous abuse of the product. 
Sadrži i nalokson koji se primjenjuje za odvraćanje od intravenske zlouporabe ovog lijeka.
The first dose of Zubsolv should be taken when signs of withdrawal appear, but not less than 24 hours after you last used methadone 
Prvu dozu lijeka Zubsolv trebate uzeti kad se pojave znakovi ustezanja, no ne ranije od 24 sata od zadnjeg uzimanja metadona.
Zubsolv tablet strength 
Jačina Zubsolv tablete
Mouth ulceration Tongue discolouration 
Ulceracije u ustima
• flu-like symptoms, infection, sore throat and painful swallowing, runny nose 
• simptomi nalik gripi, infekcija, grlobolja i bolno gutanje, curenje iz nosa
Precipitation of opioid withdrawal syndrome 
Izazivanje sindroma ustezanja od opioida
• asthma, shortness of breath, yawning 
• astma, nedostatak zraka, zijevanje